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Background: Tic disorders (TDs) are common neuropsychiatric disorders in children. Typical antipsychotics, such
as haloperidol and pimozide have been prescribed to control tic symptoms as first-line agents. However, adverse
effects have led to the use of newer atypical antipsychotics. Aripiprazole is one of alternatives. The aim of this study
was to evaluate the efficacy and safety of aripiprazole for children with TDs.
Methods: Randomized controlled trials (RCTs), quasi-RCTs and control studies evaluating aripiprazole for children
with tic disorders were identified from PubMed, Embase, Cochrane library, Cochrane Central, four Chinese database
and relevant reference lists. Quality assessment referred to the Cochrane Handbook for Systematic Reviews of
Interventions.
Results: Twelve studies involving 935 participants were included. The general quality of included studies was
poor. Only one study used placebo as a control and others used positive drug controls. Participants were
aged between 4 and 18 years. The period of treatment ranged from 8 to 12 weeks. Seven studies (N = 600
patients) used the YGTSS scale as the outcome measurement, and there was no significant difference in
reduction of the total YGTSS score between the aripiprazole and positive control groups (MD = −0.48, 95 % CI
[−6.22, 5.26], P = 0.87, I2 = 87 %). Meta-analysis of four of the studies (N = 285 patients) that compared aripiprazole
with haloperidol showed that there was no significant difference in reduction of the total YGTSS score (MD = 2.50,
95 % CI [−6.93, 11.92], P = 0.60, I2 = 88 %). Meta-analysis of two studies (N = 255 patients) that compared aripiprazole
with tiapride showed that there was no significant difference in reduction of the total YGTSS score (MD = −3.15,
95 % CI [−11.38, 5.09], P = 0.45, I2 = 86 %). Adverse events (AEs) were reported in 11 studies. Drowsiness (5.1 %–58.1 %),
increased appetite (3.2 %–25.8 %), nausea (2 %–18.8 %) and headache (2 %–16.1 %) were common AEs.
Conclusion: In conclusion, aripiprazole appears to be a promising therapy for children with TDs. Further well-
conducted RCTs are required to confirm this issue.
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Tic disorders (TDs) are common neuropsychiatric disorders
in children. These disorders are characterized by sudden,
fast, repetitive, non-rhythmic, and stereotyped motor move-
ments and/or phonic production [1]. TDs are often classi-
fied as transient tic disorder (TTD), chronic tic disorder* Correspondence: zhlingli@sina.com
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unless otherwise stated.(CTD), and Tourette syndrome (TS). Symptoms of com-
mon comorbidities of TDs (i.e., attention-deficit hyper-
activity disorder [ADHD], obsessive-compulsive disorder,
oppositional defiant disorder, and other mood disorders)
often co-exist [2]. A meta-analysis of the prevalence of
TDs showed that the prevalence of TS is 0.77 % (95 %
confidence interval [CI]: 0.39–1.51), TTD is the most
common TD, with a prevalence of 2.99 % (95 % CI: 1.60–
5.61), and CTD has a prevalence of 1.61 % (95 % CI: 0.92–
2.83) [3].
Currently, pharmacotherapy is the main management
for motor/vocal tics and comorbidity symptoms. Typical
antipsychotics, such as haloperidol and pimozide havehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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agents [4]. However, adverse effects, such as acute dys-
tonic reactions, akathisia, tardive dyskinesia, extrapyram-
idal syndrome, and prolonged QTc, are problematic and
have led to the use of newer atypical antipsychotics [5].
Among the atypical antipsychotics, the use of risperi-
done and aripiprazole for the treatment of TS has been
described in randomized controlled trials (RCTs) and
case series studies [6–12]. In 2013, a 14-week prospect-
ive open-label study [11] evaluated the efficacy of aripi-
prazole for TDs in patients who were aged between 4
and 18 years, including 81 children. This previous study
showed that the mean reduction in the motor tic score
was 51.0 %, that in the vocal tic score was 67.1 %, and
that in the total Yale Global Tic Severity Scale (YGTSS)
score was 70 % after treatment. The authors concluded
that aripiprazole is effective for the short-term treat-
ment of TD, especially vocal tics, with few adverse effects.
In 2012, another 12-week open-label study [12] assessed
the use of aripiprazole in a consecutive group of 28 pa-
tients with the primary diagnosis of TS and co-morbid
ADHD, a combined subtype. This previous study showed
that the YGTSS score and the ADHD rating scale IV sig-
nificantly improved (p < 0.001) after treatment. With re-
gard to the YGTSS, there was a reduction of 42.5 % in
motor tics, 47.9 % in vocal tics, and 32.3 % in the tic im-
pairment. A total of 67.9 % of patients had a reduction of
at least 50 % of the total YGTSS score [12]. Additionally
the results of two RCTs that were recently published
showed that aripiprazole is efficacious, generally tolerated,
and safe for TDs [9, 10].
Aripiprazole has been used to treat schizophrenia and
bipolar disorder for adults and adolescents for many
years. The mechanisms of action may be a partial agon-
ist on D2 and 5-hydroxytryptamine 1A receptors and an
antagonist on 5-hydroxytryptamine 2A receptors [13].
Aripiprazole may also have beneficial effects in patients
with TDs with a lower risk of side effects than other
atypical neuroleptics [14].
Ghanizadeh’s study [15] systematically reviewed the ef-
ficacy and safety of aripiprazole for children with TDs.
They concluded that aripiprazole is effective for treating
tic disorders including TS in children and adolescents.
Additionally, aripiprazole’s adverse effect profile is safer
than pimozide and some other antipsychotics. However,
the included studies in this systematic review have sev-
eral limitations, including a small sample size, an open-
label approach, being case reports or case series, and the
short-term nature of the studies. Recently, two RCTs
that evaluated the efficacy of aripiprazole for children
with TDs were published [9, 10]. Many studies have also
been published in China. Therefore, this systematic re-
view [15] may have missed some important information.
In addition, the newer atypical antipsychotics can reducethe risk of extrapyramidal symptoms. However, atypical
antipsychotics are associated with metabolic side effects,
including weight gain and hyperlipidemia (an abnormally
high concentration of fatty substances in the blood) [16].
Therefore, the evidence for the efficacy and safety of ari-
piprazole for children with TD needs to be updated.
Methods
Inclusion and exclusion criteria
Types of studies
All RCTs, quasi-RCTs, and open-label control studies
comparing aripiprazole with placebo or other drug(s) used
in the treatment of children with TDs were included. Tri-
als were excluded if (1) the data for children could not be
obtained (even though we attempted to contact the ori-
ginal study investigators), and (2) they compared different
doses of drugs (i.e., the treatment group used high [or
low] doses of aripiprazole and the control group used low
[or high] doses).
Types of participants
Patients with the clinical diagnosis of a TD were included.
The widely used definitions of TDs are in the following
guidelines: (1) the Diagnostic and Statistical Manual of
Mental Disorders-III (DSM-III), DSM-IV, or DSM-IV-
Text Revision [17–19]; (2) the International Classification
of Diseases-10 (ICD-10) [20]; and (3) the Chinese Classifi-
cation and Diagnostic Criteria of Mental Disorders
(CCMD) [21]. The age of participants was younger than
18 years.
Types of interventions
All RCTs, quasi-RCTs, and open-label control studies
that administered aripiprazole used either alone or as an
add-on to an approved treatment for TDs were included.
Comparisons included (1) aripiprazole versus placebo
only, (2) aripiprazole plus approved treatments versus pla-
cebo plus approved treatments, and (3) aripiprazole versus
approved treatments (i.e., haloperidol and tiapride).
Types of outcome measurements
Primary outcomes
We included studies that measured outcomes using one
of the following scales or methods: (1) the YGTSS [22];
(2) the Clinical Global Impression (CGI) Scale [23]; (3) the
Tourette Syndrome Global Scale [18]; (4) the Tourette
Syndrome Symptom List [18]; (5) the Clinical Global
Impression Tic Severity Scale [19]; and (6) the Tourette
Syndrome Severity Scale [23].
Secondary outcomes
The secondary outcomes included improvement of tic
symptoms that were assessed by authors’ self-definition
and adverse events (AEs), which were measured using
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Events [23], (2) the Abnormal Involuntary Movement
Scale, (3) the Extrapyramidal Symptom Rating Scale, (4)
weight gain, (5) abnormalities or changes on an electrocar-
diogram [18], and (6) other reported AEs.
Search strategy
Two reviewers (Yang and Huang) independently identi-
fied studies through searches of PubMed (1966–2014.6),
EMBASE (1974–2014, Issue 6), the Cochrane Library
(2014, Issue 6), Cochrane Controlled Trials databases
(CENTRAL 6, 2014), the Chinese Biomedical Literature
Database (CBM, 1978–2014.6), China National Knowledge
Infrastructure (CNKI, 1980–2014.6), the Chinese Science
and Technique Journals Database (VIP, 1989–2014.6), the
Wanfang Database (http://www.wanfangdata.com/) (1990–
2014.6), and reference lists of relevant articles. The terms
“aripiprazole”, “tourette syndrome”, “tic disorders”, and
“tics” were combined using “and” or “or” for searching
for relevant studies. The search was restricted to human
studies and the language of publications was restricted to
English or Chinese.
Selection of studies and data extraction
Two reviewers (Yang and Huang) independently screened
the titles and abstracts of every record. Full articles were
obtained when either information provided in the title or
abstracts conformed to the selection criteria outlined pre-
viously, or could not be ascertained because of limited in-
formation. To include studies, data were independentlyFig 1 Flow chart of literature screening and the selection processextracted by each reviewer and entered into a standard-
ized form. The data extraction form included the follow-
ing contents: (1) general characteristics of studies, (2) the
general characteristics of patients, (3) the diagnostic cri-
teria, (4) sample size, (5) comparisons, (6) outcome mea-
surements, and (7) AEs. Discrepancies were resolved by
consensus.
Quality assessment
Two reviewers (Yang and Huang) independently evaluated
the methodological quality of identified studies using the
“risk of bias tool” under the domains of six aspects, includ-
ing (1) sequence generation, (2) allocation concealment,
(3) blinding, (4) incomplete outcome data, (5) selective
outcome, and (6) other biases. The methodological criteria
referred to the Cochrane Handbook for Systematic Reviews
of Interventions, version 5.0.1 [24].
Statistical methods
Results for dichotomous outcomes are expressed as risk
ratios (RR) with 95 % CIs. Results for continuous outcomes
are expressed as the mean difference (MD) (if the same
scale for each trial was available) or standardized mean
difference (if different scales were used). We evaluated
heterogeneity among the included studies using the I2 test.
We considered a value greater than 50 % to indicate sub-
stantial heterogeneity and sought the potential sources of
heterogeneity (clinical heterogeneity and methodological
heterogeneity). Regardless of the size of heterogeneity, the
random effects model was used for statistical analysis. We
Table 1 General characteristics of included studies
Study Characteristics of participants Interventions Treatment
period
(weeks)







Treatment group Control group
Ghanizadeh
2013 [9]
6-18 years; 60(49) Comparable Aripiprazole (initial dose: 1.25
mg/day, gradually increase
dose, final dose: 10–15 mg/day)
Risperidone (initial dose: 0.25
mg, gradually increase dose,
final dose: 2-3 mg/d)
8 1. YGTSS score DSM-IV-TR
Tic disorder Baseline T*: 30.5 ± 13.4, C†: 31.7 ± 10.0 YGTSS ≥
21
After treatment T*: 12.8 ± 12, C†:19.3 ± 12.5
2. Motor tic severity score
Baseline T*: 13.1 ± 4.1, C†: 12.9 ± 3.8
After treatment T*: 4.0 ± 4.5, C†:6.0 ± 4.3
3. Vocal tic severity score
Baseline T*: 4.0 ± 4.1, C†: 6.1 ± 5.1
After treatment T*: 0.7 ± 1.8, C†:3.0 ± 3.8
4. Total tic severity scores
Baseline T*: 16.5 ± 6.4, C†: 19.0 ± 7.3
After treatment T*: 5.7 ± 6.2, C†:9.9 ± 7.7
Yoo 2013 [10] 6-18 years
Tourette
syndrome








9 1. Total tic severity scores DSM-IV
Baseline T*: 28.3 ± 5.5, C†: 29.5 ± 5.6 YGTSS ≥
22
After treatment T*: 13.6 ± 9.1, C†:19.9 ± 9.5
2. Motor tic severity score
Baseline T*: 15.9 ± 4.0, C†: 17.3 ± 3.2
After treatment T*: 8.6 ± 6.1, C†:11.9 ± 5.5
3. Vocal tic severity score
Baseline T*: 12.4 ± 3.7, C†: 12.2 ± 4.4
After treatment T*: 5.0 ± 4.6, C†:8.0 ± 5.5
4. Tourette’s syndrome clinical global
Baseline T*: 4.5 ± 0.8, C†: 4.7 ± 0.8
After treatment T*: 2.8 ± 1.4, C†:3.6 ± 1.3
Yoo 2011 [14] 6-15 years;
Tic disorder
48(33) Comparable Aripiprazole (initial dose:
5 mg/d, increments every
2 weeks: 5–10 mg/d, maximum
dose: 20 mg/d)
Haloperidol (initial dose
0.75 mg/d and increased in
1.5–3 mg/day increments
every 2 weeks, maximum
dose: 4.5 mg/d
8 1. Total tic severity scores: DSM-IV
Baseline T*: 26.5 ± 4.9, C†: 27.6 ± 7.3 YGTSS ≥
22
After treatment T*:12.1 ± 6.4, C†: 10.1 ± 7.5.
2. Motor tic severity scores:
Baseline T*: 17.5 ± 5.3, C†: 20.5 ± 3.1
After treatment T*: 8.0 ± 4.4, C†: 8.5 ± 6.7
3. Vocal tic severity score:
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After treatment T* 4.5 ± 4.6, C†: 2.4 ± 4.3
Wang 2013 [25] 6-15 years;
Tourette
syndrome
60(41) Unclear Aripiprazole (initial dose:
2.5 mg/d, maximum dose:
10 mg/d)
Tiapride: (initial dose:
50 mg/d, maximum dose:
300 mg/d)
8 1. YGTSS score ICD-10
Baseline T*: 70.8 ± 9.9, C†: 70.1 ± 9.6
After treatment T*:44.5 ± 7.9, C†: 51.8 ± 8.3
2. Motor tic severity score
Baseline T*: 24.8 ± 6.5, C†: 23.1 ± 5.8
After treatment T*: 8.7 ± 6.3, C†: 9.5 ± 5.8
3. Vocal tic severity score
Baseline T*: 18.8 ± 8.4, C†: 18.8 ± 8.4
After treatment T*: 9.6 ± 7.8, C†: 11.5 ± 7.1
4. Impairment score:
Baseline T*: 31.4 ± 8.3, C†: 30.5 ± 8.8
After treatment T*:18.9 ± 7.8, C†: 22.4 ± 7.8
Liu 2010 [26] 6-14 years;
Tic disorder
65(57) Comparable Aripiprazole (initial dose:2.5
mg, qd, increase dose every
week:
Tiapride (initial dose: 25 mg,
bid, increase dose every
week: 25 mg, maximum dose:
400 mg/d.
12 1. Author self-defined tics symptom
improvement
DSM-IV-TR
(Rate of progress in tics symptom ≥ 30 %)
2.5 mg, maximum dose:
10 mg/d) T*:91 %(30/33), C†: 84 %(26/31)
2. Decreased YGTSS score
T*: 64 ± 23, C†: 63 ± 25
3. Decreased motor tic severity score
T*: 68 ± 15, C†: 61 ± 15
4. Decreased vocal tic severity score
T*: 68 ± 15, C†: 61 ± 15
5. Decrease impairment score
T*: 59 ± 42, C†: 63 ± 48
Liu 2011 [27] 5-17 years;
Tourette
syndrome
195(156) Comparable Aripiprazole (Age < 8 years:
initial dose: 2.5 mg, qd,
increase dose every week:2.5
mg, final dose 5-15 mg/d, qd.
Age > 8 years:
Tiapride (Age < 8 years:
initial dose: 25 mg, bid,
increase dose every week: 50
mg, final dose 100-300 mg/d,
bid or tid. Age > 8 years: initial
dose 50 mg, bid, increase
dose every week: 100 mg,
final dose: 200-500 mg/d,
bid or tid)
12 1. YGTSS score DSM-IV-TR
Baseline T*: 53.74 ± 15.71, C†: 51.66 ± 13.63 YGTSS ≥
25
After treatment T*: 24.36 ± 16.38,
C†: 23.26.1 ± 15.31
initial dose 5 mg, qd, increase
dose every week: 5 mg, final
dose: 10-25 mg/d, qd)
2. Motor tic severity score
Baseline T*: 15.93 ± 3.22, C†: 15.08 ± 2.97
After treatment T*: 7.69 ± 4.14, C†: 7.45 ± 3.42
3. Vocal tic severity score
Baseline T*: 11.99 ± 4.90, C†: 11.63 ± 3.88
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4. Impairment score
Baseline T*: 25.71 ± 10.35, C†: 24.85 ± 9.37
After treatment T*: 12.45±9.95, C†: 11.96.1 ± 9.86
Cheng 2012
[28]
T*:8.1 ± 2.9 62(39) Unclear Aripiprazole
(initial dose:2.5 mg, maximum
dose: 10 mg/d)
Haloperidol (initial dose:
0.5 mg, maximum dose:
10 mg/d)
8 YGTSS score CCMD-3
C†:7.9 ± 3.2; Baseline T*: 64.15 ± 15.52, C†: 66.34 ± 15.37
Tic disorder After treatment T*: 17.59 ± 15.12,C†:25.05 ± 16.81
Ren 2012 [29] 5-16 years;
Tic disorder
68(58) Comparable Aripiprazole (initial dose:
2.5 mg/d, gradually increase
dose, final dose: 5-20 mg/d)
Haloperidol (initial dose:
1 mg/d, gradually increase
dose, final dose: 2-8 mg/d)
8 1. YGTSS score DSM-IV-TR
Baseline T*:55.32 ± 12.23, C†:54.56 ± 13.08 YGTSS ≥
25
After treatment T*: 21.52±18.32, C†: 20.98±16.45
2. Author self-defined tics symptom improvement
(Rate of progress in tics symptom ≥30 %)
T*:79 %(26/33), C†: 73 %(22/30)
Zhao 2011 [30] 4-15 years;
Tic disorder
108(72) Comparable Aripiprazole (initial dose: 5 mg,
maintenance dose: 5-15 mg/d)
Haloperidol (initial dose:2 mg,
maintenance dose: 2-12 mg/d)
8 CGI scale CCMD-3
T*:81.3 %(44/54), C†: 82.8 % (39/47)
Guo 2013[31] 4-16 years; Tic
disorder
80(55) Comparable Aripiprazole
(initial dose:2.5 mg, maximum
dose: 12.5 mg, average daily
dose: 7.8 ± 1.1 mg)
Haloperidol (initial dose:1 mg,
maximum dose: 16 mg,
average daily dose:5.7 ± 0.8 mg)
8 YGTSS score ICD-10
Baseline T*: 65.43 ± 9.64, C†: 66.37 ± 10.16 YGTSS ≥
25
After treatment T*: 20.17 ± 10.32, C†: 19.87 ±
9.83
Gao 2013 [32] T*:11.2 ±
3.5;C†:8.6 ± 2.9;
Tic disorder
48(33) Comparable Aripiprazole (initial dose:2.5
mg/d, increase dose every
week: 2.5-5.0 mg/d, maximum
dose: 20 mg/d)
Haloperidol (initial dose:
1 mg/d, increase dose every
week: 2 mg/d, maximum dose:
8 mg/d.
8 1.Total tic severity score CCMD-3
Baseline T*: 26.5 ± 4.9, C†: 27.6 ± 7.3 YGTSS ≥
22
After treatment T*: 12.1 ± 6.4, C†: 10.1 ± 7.5
2. Motor tic severity score
Baseline T*: 17.5 ± 5.3, C†: 20.5 ± 3.1
After treatment T*: 8.0 ± 4.4, C†: 8.5 ± 6.7
3. Vocal tic severity score
Baseline T*: 9.0 ± 6.7, C†: 7.1 ± 8.3
After treatment T*: 4.5 ± 4.6, C†: 2.4 ± 4.3
Liang 2010 [33] 4-16 years;
Tourette
syndrome
80(64) Comparable Aripiprazole (5–30 mg/d) Haloperidol (6–16 mg/d) 8 YGTSS score ICD-10
Baseline T*: 54.95 ± 13.98, C†: 52.97 ± 13.54 YGTSS ≥
25
After treatment T*: 35.12 ± 13.83, C†:
19.26 ± 14.24
Total Tic Severity Score = Motor Tic Severity score + Vocal Tic Severity score (0–50), Total Yale Global Tic Severity Scale Score = Total Tic Severity Score + Impairment score (0–100)
Decreased YGTSS score: (tics scores before treatment- tics scores after treatment) /tics scores before treatment
Rate of progress in tics symptom: (tics scores before treatment- tics scores after treatment) /tics scores before treatment
CCMD Chinese classification and diagnostic criteria of mental disorders; DSM-IV diagnostic and statistical manual of mental disorder-IV; DSM-IV-TR diagnostic and statistical manual of mental disorder-IV-Text Revision;
ICD-10 international code of diseases;
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We planned to assess publication bias by following the
recommendations on testing for funnel plot asymmetry
according to the Cochrane Handbook for Systematic Re-
views on Interventions [24]. We visually assessed funnel
plot asymmetry.
Results
Results of the literature search
A total of 204 articles were retrieved from searching
electronic databases and reference lists (Fig. 1). After re-
moving duplicate articles and screening titles, abstracts,
and full texts, 12 studies were included in this review.
Characteristics of included studies
We included 12 studies involving 935 participants (710
were male). The sample size ranged from 48 to 195 cases.
Participants were aged between 4 and 18 years. The pro-
portion of male participants was 76 % (710/935). Nine
studies were conducted in mainland China, two in Korea
[10, 14], and one in Iran [9]. All of the studies used
pharmacological interventions. Eleven studies were posi-
tive drug controls, which were defined as the control
group having an active control (i.e., test drug versus con-
trol drug, or standard treatment plus test drug versus
standard treatment plus control drug). Of these 11 studies,
seven studies used haloperidol as a control, three studies
[25–27] used tiapride and one study [9] used risperidone.
Only one study used placebo as a control [10]. For diag-
nostic criteria, six studies used the DSM-IV (four studies
used the DSM-IV-Text Revision and two used the DSM-
IV), three studies used the CCMD, and three studies used






Ghanizadeh2013 [9] Low risk Low risk
Yoo 2013 [10] Unclear Unclear
Yoo 2011 [14] a High risk Unclear
Wang 2013 [25] High risk Unclear
Liu 2010 [26] Unclear Unclear
Liu 2011 [27] High risk Unclear
Cheng 2012 [28] Unclear Unclear
Ren 2012 [29] a Low risk Unclear
Zhao 2011 [30] High risk Unclear
Guo 2013[31] Unclear Unclear
Gao 2013 [32] a Low risk Unclear
Liang 2010 [33] High risk Unclear
a: they are open-label studies which did not use the method of blinding, so we just
we justify them as unclearthe CGI Scale, and two studies used self-defined criteria by
the authors for measurement of outcome. The period of
treatment ranged from 8 to 12 weeks. See Table 1.
Quality assessment
Twenty-five percent (3/12) of studies used an adequate
method of random sequence generation [9, 29, 32]. One
third (4/12) of the studies only mentioned “random allo-
cation” without a specific description. Only one study
[9] implemented adequate allocation concealment and
blinding, three studies were open-label studies and did
not use the method of blinding [14, 28, 33], and the
remaining studies did not mention the details of blind-
ing. Fifty percent (6/12) of studies reported loss to
follow-up, and none of the studies used an intention-to-
treat analysis for incomplete outcome data. One study
stated that the reasons for loss to follow-up did not differ
between two groups [10]. Only one of the studies had regis-
tration for a protocol [10]. Therefore, whether there was se-
lective reporting was unclear. Comparability of baseline
in two of the studies was unclear [25, 28]. In other
trials, there were no significant differences in the compar-
ability of baseline between the treatment group and the
control group. See Table 2.
Analysis of efficacy and safety
Primary outcome measurements
Evaluation of efficacy by using the YGTSS One ran-
domized, double-blind, placebo-controlled study [10] used
the total YGTSS score as the outcome measurement,
and showed a significant difference in reduction of the
total YGTSS score (13.6 ± 9.1 vs 19.9 ± 9.5, P < 0.05) and






Low risk Low risk Unclear Low risk
Unclear Low risk Low risk Low risk
High risk Low risk Unclear Low risk
Unclear Low risk Unclear High risk
Unclear Unclear Unclear Low risk
Unclear Unclear Unclear Low risk
Unclear Low risk Unclear High risk
High risk Unclear Unclear Low risk
Unclear Unclear Unclear Low risk
Unclear Low risk Unclear Low risk
High risk Unclear Unclear Low risk
Unclear Low risk Unclear Low risk
ify them as high risk. Many studies did not mention the details of blinding, so
Fig 2 Meta-analysis of symptom improvement assessed by YGTSS Total Score
Fig 3 Meta-analysis of symptom improvement assessed by YGTSS Vocal Tics Score
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Fig 4 Meta-analysis of symptom improvement assessed by YGTSS Motor Tics Score
Yang et al. BMC Psychiatry  (2015) 15:179 Page 9 of 15aripiprazole and placebo. There was no significant differ-
ence in reduction of the motor tic score (8.6 ± 6.1 vs 11.9
± 5.5, P > 0.05). A total of seven studies (N = 600 patients)
used the YGTSS scale as the outcome measurement, and
there was no significant difference in reduction of the total
YGTSS score between the aripiprazole and positive con-
trol groups (MD= −0.48, 95 % CI [−6.22, 5.26], P = 0.87,
I2 = 87 %) (Fig. 2) during the treatment period. Of them,
meta-analysis of four of the studies (N = 285 patients) that
compared aripiprazole with haloperidol showed that thereFig 5 Meta-analysis of symptom improvement assessed by YGTSS Total Ticwas no significant difference in reduction of the total
YGTSS score between the two groups (MD= 2.50, 95 %
CI [−6.93, 11.92], P = 0.60, I2 = 88 %) [28, 29, 31, 33].
Meta-analysis of two studies (N = 255 patients) that com-
pared aripiprazole with tiapride showed that there was no
significant difference in reduction of the total YGTSS
score between the two groups (MD= −3.15, 95 % CI
[−11.38, 5.09], P = 0.45, I2 = 86 %) [25, 27]. One study
(N = 60 patients) showed that there was a significant dif-
ference in reduction of the total YGTSS score betweens Score
Fig 6 Meta-analysis of symptom improvement assessed by YGTSS Impairment Score
Yang et al. BMC Psychiatry  (2015) 15:179 Page 10 of 15aripiprazole and risperidone (12.8 ± 12 vs 19.3 ± 12.5,
P < 0.001), but aripiprazole was not superior to risperi-
done for improving the YGTSS (MD = −6.50, 95 % CI
[−12.71, −0.29], P = 0.04) [9].
Five studies (N = 411 patients) evaluated motor and
vocal tics, and showed no significant difference in reduc-
tion of the vocal tics score (MD= 0.07, 95 % CI [−1.70,
1.84], P = 0.94, I2 = 74 %) (Fig. 3) and the motor tics score
(MD= −0.26, 95 % CI [−1.13, 0.60], P = 0.55, I2 = 0) (Fig. 4)
between the aripiprazole and positive control groups.
Three studies (N = 156 patients) evaluated the total
tic score, and showed no significant difference in reduc-
tion of the total tic score (MD= −0.2, 95 % CI [−4.47,
4.06], P = 0.93, I2 = 71 %) (Fig. 5). Two studies (N = 255
patients) evaluated the impairment score and also showed
no significant difference in reduction of the impairment
score (MD= −0.83, 95 % CI [−3.11, 1.44], P = 0.47, I2 =
62 %) (Fig. 6).
Evaluation of efficacy by using the CGI Scale One
study used the CGI Scale as the outcome measure, and
showed no significant difference in the rate of clinicalFig 7 Meta-analysis of tics symptom improvement assessed by tics symptoefficacy between aripiprazole and haloperidol (81.3 %
[44/54] vs 82.8 % [39/47], P > 0.05) [30].
Evaluation of efficacy by using the Tourette Syndrome
Global Scale One study used the Tourette Syndrome
Global Scale as the outcome measure, and showed a sig-
nificant difference in the Tourette Syndrome Global
Scale between aripiprazole and placebo (MD = −0.80,
95 % CI [−1.48, −0.12], P = 0.02) [10].
Secondary outcome measurements
Efficacy of improvement of tic symptoms that were
self-defined by authors Meta-analysis of two studies
(N = 127 patients) used the rate of progress in tic symptoms
≥30 % as the outcome measure. There was no significant
difference between the aripiprazole and positive control
groups (RR = 1.54, 95 % CI [0.61, 3.88], P = 0.36, I2 = 0) [29,
31]. See Fig. 7.
AEs
All of the studies reported specific AEs, except for one
study [30]. The most common AEs of aripiprazole werem improvement by author self-defined
Table 3 The reported AEs of included studies




Drowsiness:5.1 %(5/98)–58.1 %(18/31); Drowsiness: 6.67 %(2/30)–82.4 %(14/17); Dizziness: 3.1 %(3/97)–6.67 %(2/30); Drowsiness:17.2 %(5/29);
Extrapyramidal symptoms: 6.45 %(2/33)–19.4 %(6/31); Extrapyramidal symptoms: 40 %(12/30)–43.6 %(17/39); Drowsiness: 3.23 %(1/31)–5.2 %(5/97); Fatigue: 3.4 %(1/29);
Headache: 2 %(2/98)–16.1 %(5/31); Tremor: 19.4 %(6/31)–22.5 %(9/40); Anxiety: 13.3 %(4/30); Dizziness: 3.4 %(1/29);
Akathisia:3.33 %(1/30)–6.3 %(2/32); Headache: 58.8 %(10/17); Sedation: 6.67 %(2/30); Nausea: 3.4 %(1/29);
Anxiety: 2 %(2/98)–6.45 %(2/31); Tremor:
3.23 %(1/31)–5 %(2/40);
Dizziness: 11.8 %(2/17); Akathisia: 6.67 %(2/30);
Fatigue: 2 %(2/98)–9.7 %(3/31); Emotional hypersensitivity: 11.8 %(2/17); Fatigue: 3.1 %(3/97);
Dizziness: 2.44 %(1/41)–6.5 %(2/31); Insomnia: 11.8 %(2/17); Irritability:11.8 %(2/17);
Fatigue: 7.69 %(3/39); Nightmare: 5.9 %(1/17);
Headache: 2.1 %(2/97);
Insomnia: 1 %(1/98)–3.2 %(1/31); Sedation:12.5 %(4/32); Insomnia : 2.1 %(2/97);
Slowness: 6.5 %(2/31); Tiredness: 4.88 %(2/41);
Emotional hypersensitivity: 3.2 %(1/31); Irritability:
3.2 % (1/31);
Nightmare: 3.2 %(1/31)
Digestive system Increased appetite: 3.2 %(1/31)–25.8 %(8/31); Nausea/vomiting: 23.5 %(4/17); Nausea: 3.1 %(3/97)–13.3 %(4/30); Increased appetite:
Anorexia: 4.1 %(4/98)–15 %(6/40); Nausea:
2 %(2/98)–18.8 %(6/32);
Nausea: 16.1 %(5/31); Anorexia: 3.23 %(1/31)–4.1 %(4/97); 27.6 %(8/29);
Nausea/vomiting:1 %(1/98)–29 %(9/31); Gastrointestinal disturbances: 11.8 %(2/17); Nausea/vomiting: 2.1 %(2/97); Abdominal pain:
6.9 %(2/29);
Decreased Appetite: 12.9 %(4/31); Abdominal pain
9.7 %(3/31);
Anorexia: 7.5 %(3/40)–11.8 %(2/17);
Gastrointestinal disturbances: 6.5 %(2/31); Dyspepsia:
3.1 %(1/32);
Constipation: 6.45 %(2/31);
Abnormal liver function: 1 %(1/98); Increased appetite: 5.9 %(1/17)




Weight gain: 1 %(1/98); Polydipsia: 3.2 %(1/31) - - -




Elecrocardiogram QT prolonged: 6.3 %(2/32); Electrocardiographic abnormality:
6.45 %(2/31)–10 %(4/40);
- -
Electrocardiographic abnormality: 2.5 %(1/40)–6.45 %(2/31); Chest discomfort: 11.8 %(2/17)
Chest discomfort: 3.2 % (1/31)
Respiratory
system
Nasopharyngitis: 12.5 %(4/32); - - -
Upper respiratory tract infection: 3.1 %(1/32);











Table 3 The reported AEs of included studies (Continued)
Others Dry mouth: 6.5 %(2/31)–6.67 %(2/30); Dry mouth: 5 %(2/40)–19.4 %(6/31); Dry mouth: 10 %(3/30); -
Tiredness: 15.4 %(6/39); Joint pain: 11.8 %(2/17);
Febrile sense: 5.9 %(1/17);
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AEs of haloperidol and tiapride were drowsiness, extra-
pyramidal symptoms, nausea, and dizziness. The most
common AEs of risperidone were increased appetite,
drowsiness, and diurnal urinary incontinency. The most
common AEs of placebo were dizziness, akathisia and
sedation. The common AEs of different drugs are shown
in Table 3.
Publication bias
In this study, we visually assessed funnel plot asymmetry
for the included studies that used the YGTSS for evalu-
ation of efficacy. Figure 8 shows that the funnel plot was
asymmetric.
Discussion
In this systematic review, we analyzed the efficacy and
safety of aripiprazole for children with TDs, we found simi-
lar findings of efficacy among a variety of studies that
compared aripiprazole and an active agent or placebo.
Some studies showed that aripiprazole improved the
YGTSS scores in patients with TD. Although the quality
of some studies was generally poor, at least they were safe
because there were no severe AEs. In general, aripiprazole
was well tolerated. The most common AEs of aripiprazole
were drowsiness, increased appetite, nausea, and headache.
Tardive dyskinesia was observed in the typical antipsy-
chotics (i.e., haloperidol and pimozide). To minimize such
side effects, atypical antipsychotics have been prescribed
for patients with TDs as alternatives. Because of a lack ofFig 8 Funnel plot asymmetry for the included studies which using YGTSS Slong-term evaluation of outcomes, some AEs was not ob-
served in current studies. Long-term side effects of aripi-
prazole should be monitored in further studies.
The quality of the included studies in our review was
generally poor. The main problems are as follows. Most
studies were often labeled as “random” without provid-
ing details on random sequence generation. Only one
study implemented adequate allocation concealment and
blinding. Successful implementation of an adequately
concealed randomization sequence and blinding were
not reported. Most studies used a positive drug control
as a control group, with a lack of placebo controls.
Seven studies used the YGTSS as the outcome measure-
ment, but we found large heterogeneity in the meta-analysis.
The potential reasons for this large heterogeneity may be
as follows. (1) Only participants with a YGTSS score >25
points were included in four studies [27, 29, 31, 33,
35], the YGTSS score was >22 points in three studies
[10, 14, 32], and the YGTSS score was >21 in one study
[9]. (2) There were different diagnostic criteria that
were used between studies. Three studies used the DSM-
IV-Text Revision [9, 27, 29], three studies used the ICD-
10 [25, 31, 33], and one study used the CCMD-3 [28]. Pa-
tients in three of the studies [25, 27, 33] were diag-
nosed with TS and the other patients had TDs. (3)
There were differences in intervention and dose be-
tween studies. Four studies used haloperidol as a control,
two studies used tiapride, and one study used risperi-
done. The initial and maximum dose varied in these
included studies.cale for efficacy evaluation
Yang et al. BMC Psychiatry  (2015) 15:179 Page 14 of 15TS is defined by the onset of motor and vocal tics in
children, lasting more than 12 months. Although TS is the
most notorious cause of chronic tics, there are types of
TDs that are more common in children than in adults.
According to the DSM-IV of the American Psychiatric
Association, other TDs include chronic motor TD and
chronic vocal TD, which are defined as having motor or
phonic tics (but not both) for more than 12 months. TTD
is characterized by tics (either motor and/or vocal) for a
duration of less than 12 months [35]. TS is often associated
with behavioral problems, such as ADHD and obsessive-
compulsive disorder [35], and is more difficult to treat than
other TDs. In our study, four studies evaluated the efficacy
of aripiprazole for TS, and in all of them, the YGTSS score
was significantly reduced from baseline to after treatment.
Therefore, the efficacy of aripiprazole for TS is promising.
There are several limitations to our study. (1) Most of
the included studies were conducted in a single center
with a small sample (48–195 cases), and were conducted
in China. Therefore, the efficacy of aripiprazole needs to
be tested in other ethnicities. (2) The outcome measure-
ments varied across different studies, which made it dif-
ficult to compare the efficacy among different studies.
(3) The majority of studies used positive drugs as con-
trols, with a lack of reasonable placebo controls. (4)
There was a lack of long-term evaluation of outcomes in
the included studies. AEs, such as metabolic side effects
and tardive dyskinesia, were not observed in current
studies. Long-term side effects of aripiprazole need to be
monitored in further studies. (5) Monitoring the quality
of implications and reporting of trials was difficult be-
cause of the lack of clinical trial registration, and publi-
cation bias may exist.
Conclusions
In conclusion, aripiprazole appears to be a promising ther-
apy for children with TDs. Further well-conducted RCTs
are required to confirm this issue.
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